This inventor holds 1 USPTO granted patent. Top assignee: Merck + Co., Inc.. Active years: 1992.
Company Filing History:
Years Active: 1992
Title: Eli Roubini: Innovator in Peptide Analogues
Introduction
Eli Roubini is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of biochemistry, particularly in the development of peptide analogues. His work focuses on the mechanisms that can inhibit naturally occurring peptides, which has implications for various medical applications.
Latest Patents
Eli Roubini holds a patent for "Humoral hypercalcemic factor antagonists." This patent describes peptide analogues of human humoral hypercalcemic factor (hHCF) that contain a lactam bridge, which acts as an inhibitor of the naturally occurring peptide. The lactam bridge between Lys and Asp, situated five residues apart, confers rigidity to that region of the peptide. This innovation enhances the helical nature and metabolic stability of the peptide analogue, showcasing Roubini's expertise in peptide design.
Career Highlights
Eli Roubini is currently associated with Merck & Co., Inc., a leading global healthcare company. His role at Merck allows him to collaborate with other experts in the field and contribute to groundbreaking research and development in pharmaceuticals.
Collaborations
Eli Roubini has worked closely with his coworker, Michael Chorev. Their collaboration has likely fostered innovative ideas and advancements in their research endeavors.
Conclusion
Eli Roubini's contributions to the field of peptide analogues demonstrate his innovative spirit and commitment to advancing medical science. His patent on humoral hypercalcemic factor antagonists highlights the potential for new therapeutic approaches.